by EpicentRx | May 29, 2024 | Blog
“BOOM!” emailed Dr. Anthony P. Conley to us after having received notice that he was selected to give an oral presentation on lead EpicentRx therapy, AdAPT-001, plus a checkpoint inhibitor at #ASCO2024. Actually, the “BOOM!” was bigger than that, both literally...
by EpicentRx | May 29, 2024 | Blog
It is a real challenge to get an abstract accepted at ASCO, so this week in the lead-up to the big conference, ASCO24, we set ourselves a just-for-fun, and considerably easier challenge, at least by comparison: to write a blog where we use ASCO as an adjective, verb,...
by EpicentRx | May 28, 2024 | Blog
Captain’s blog Stardate 5/28/2024 We’ve officially taken the plunge and launched a YouTube channel dedicated to video blogging or “vlogging” all-original EpicentRx-related content. After much back-and-forth with our dedicated PR and communications team, Ashley (“AT”),...
by EpicentRx | May 28, 2024 | Blog
“Innovaaaation is making us great.”Sung to the tune of the Heinz “Anticipaaaation” ketchup commercial from the 1970s, shown below.Disruptive Innovation noundis-ruhp-tiv in-uh-vay-shuhnDefinition: Any type of transformative innovation that “disrupts” and...
by EpicentRx | May 24, 2024 | Blog
Just exactly how prestigious is it to be selected for an Oral Presentation at the American Society for Clinical Oncology (ASCO)? Very prestigious. Way, way prestigious. One statistic clearly makes the point: this year out of over 7000 submitted abstracts only around...
